Shares of 4DMedical fell sharply again this week, dropping 15.57%, or 59 cents, to $3.20, extending a punishing stretch for one of the Australian Securities Exchange's most volatile healthcare names as investors continue reassessing the medical imaging company's valuation following a spectacular run-up earlier this year.

The latest decline builds on a selloff that has been building for weeks. Shares fell 5.64% to $3.68 during Thursday's session, a move that came without any confirmed company-specific announcement, according to market data, suggesting the drop reflected broader trading sentiment rather than a specific catalyst. That followed an even steeper plunge earlier in the year, when the stock closed down 10.53% at $3.40 in a single session, part of a broader reversal that has now wiped out more than half of the company's value from its April peak.

4DMedical, listed on the ASX under the ticker 4DX, develops medical imaging technology aimed at improving the diagnosis and monitoring of respiratory diseases. The company's proprietary imaging platform is designed to provide functional lung analysis without the need for invasive procedures, and its technology is used across both clinical and research settings. The company's broader commercial strategy has focused on expanding adoption of its imaging platform while pursuing regulatory approvals, new partnerships and additional healthcare applications for its technology.

The stock's recent volatility stands in sharp contrast to the extraordinary rally that preceded it. 4DMedical shares surged approximately 1,000% over the trailing twelve........

© International Business Times